Fortis

Biotec Pharmacon ASA (OSL:BIOTEC) Biotec Pharmacon ASA has entered into a new market making agreement for the company`s shares. The agreement is entered into with DnB NOR Markets who undertakes to quote bid- and offer prices in the share for at least 4 round lots and with a maximum spread of 4%. The agreement is based on Oslo Børs` requirements for liquidity provider agreements, and will become effective starting from January 26th, 2009. The agreement replaces the previous market maker agreement with SEB Enskilda.

Biotec Pharmacon ASA (OSL:BIOTEC) Oslo 13 January, 2009: Biotec Pharmacon is experiencing a faster than expected patient enrolment in the second of its two phase III studies with SBG for treatment of diabetic ulcers. However, the oral mucositis program is developing somewhat slower than planned. Patient enrolment for the new phase III diabetic ulcers study commenced in November, and 40 percent of the total planned patient population has already been included in the study. In the other phase III study - the "Nottingham-study" - more than 100 of targeted 120 patients have now been enrolled, and Biotec Pharmacon confirms its target to file for marketing authorisation with SBG for treatment of diabetic ulcers in mid-2010. "We are glad to see that most of the clinical centers we have chosen have shown a strong commitment to our diabetic ulcers studies. The fast patient enrolment lends confidence to our milestone schedule with SBG for this common and serious medical condition," says CEO Lar ...

Biotec Pharmacon ASA (OSL:BIOTEC) (Oslo/Tromsø, 17 December 2008) Biotec Pharmacon ASA has started deliveries of Cod-UNG enzyme to Siemens Healthcare Diagnostics, who will use the enzyme in a new diagnostic product for quantification of HIV-1 (Link: Siemens Introduces Next-Generation Molecular Diagnostics Technology for HIV-1 Viral Load Test).

Biotec Pharmacon ASA (OSL:BIOTEC) Sven Rohmann, Vice President Business Development at Biotec Pharmacon, has today bought 7,000 shares in the company at a price of 11.20 NOK per share. After this transaction Sven Rohmann owns 31,000 shares in Biotec Pharmacon.

Biotec Pharmacon ASA (OSL:BIOTEC) Sven Rohmann, Vice President Business Development at Biotec Pharmacon, has bought 24000 shares in the company at an average price of 11.6208 NOK per share. After this transaction Sven Rohmann owns 24 000 shares in Biotec Pharmacon.

Biotec Pharmacon ASA (OSL:BIOTEC) The market maker agreement between SEB Enskilda AS and the Company published 28. June 2007 has been terminated by SEB Enskilda. The termination will be effective as of 25. January 2009.

Biotec Pharmacon ASA (OSL:BIOTEC) The market maker agreement between SEB Enskilda AS and the Company published 28. June 2007 has been terminated by SEB Enskilda. SEB Enskilda has decided to terminate all such agreements. The termination will be effective as of 25. January 2009.

Biotec Pharmacon ASA (OSL:BIOTEC) Financial calendar 2009 for Biotec Pharmacon ASA:

Biotec Pharmacon ASA (OSL:BIOTEC) Results from a blinded interim analysis did not prompt Biotec Pharmacon to make any changes to the sample size of its phase III study with SBG (soluble beta-glucan) for treatment of diabetic ulcers. The interim analysis was carried out on the first of two phase III studies for this indication to assess whether the planned study population of 120 patients would be sufficiently large to provide a conclusive, statistically significant result.

Biotec Pharmacon ASA (OSL:BIOTEC) The first 3 patients have been enrolled in the second of Biotec Pharmacon's two phase III-studies with SBG for treatment of diabetic ulcers. An estimated 3.5 million diabetes patients in the OECD-area annually develop foot and leg ulcers, for which there are no well-established treatments available. These ulcers often develop into a chronic condition with high risk of infections, which in many cases may end with amputation. Results from Biotec Pharmacon's first phase III-study is expected during 2009, and the company targets filing for marketing authorisations for SBG for this indication mid-2010.